SIR, standardised incidence ratio

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
M H Schiff, G R Burmester, J D Kent, A L Pangan, H Kupper, S B Fitzpatrick, C Donovan

Annals of the Rheumatic Diseases Jul 2006, 65 (7) 889-894; DOI: 10.1136/ard.2005.043166
Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors
E Theander, G Henriksson, O Ljungberg, T Mandl, R Manthorpe, L T H Jacobsson

Annals of the Rheumatic Diseases Jun 2006, 65 (6) 796-803; DOI: 10.1136/ard.2005.041186
Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis
Anna Södergren, Birgitta Stegmayr, Vivan Lundberg, Marie-Louise Öhman, Solveig Wållberg-Jonsson

Annals of the Rheumatic Diseases Feb 2007, 66 (2) 263-266; DOI: 10.1136/ard.2006.052456
Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study
M E Weinblatt, E C Keystone, D E Furst, A F Kavanaugh, E K Chartash, O G Segurado

Annals of the Rheumatic Diseases Jun 2006, 65 (6) 753-759; DOI: 10.1136/ard.2005.044404
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial
Gerd R Burmester, Xavier Mariette, Carlomaurizio Montecucco, Indalecio Monteagudo-Sáez, Michel Malaise, Athanasios G Tzioufas, Johannes W J Bijlsma, Kristina Unnebrink, Sonja Kary, Hartmut Kupper

Annals of the Rheumatic Diseases Jun 2007, 66 (6) 732-739; DOI: 10.1136/ard.2006.066761

Log in using your username and password

Main menu

Log in using your username and password

You are here

SIR, standardised incidence ratio